Finally, we assessed the effects of uPA inhibition on tumour growth and metastasis using the uPA inhibitor BB230F at 3mg (U3) and 10mg (U10)/kg body weight alongside the standard of care drug gemcitabine in an early intervention orthotopic xenograft mouse model of pancreatic cancer (Figure 14A). This evidence concerns the gene PLAU and familial pancreatic carcinoma.